Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire gets EMA Committee positive opinion for Intuniv to treat ADHD
The CHMP’s positive opinion is based on results from three Phase 3 pivotal studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents
The CHMP’s positive opinion is based on results from three Phase 3 pivotal studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents
The patent covers a method of treating eye conditions using EyeGate’s proprietary Dexamethasone Phosphate pharmaceutical formulation delivered by ocular iontophoresis. The patent is not limited to any particular
Naramin relieves the symptoms of hayfever/allergy including sneezing, runny nose, itchy watery eyes and itchy throat. It’s easy to carry for people on-the-go when you fly, camp, fish
This 505(b)(2) NDA requests FDA approval of Eagle’s RTU bivalirudin product for the treatment of patients: undergoing percutaneous coronary intervention (PCI) with use of glycoprotein IIb/IIIa inhibitor, undergoing
The proprietary combination of salts and amino acids has been engineered to create small and dense particles possessing properties that have the potential to enable or improve new
Based on the results presented at the biannual meeting July 10th in Heidelberg, Germany, Merck Serono decided to extend the funding of the first two international research groups
The EMA will initiate review of the MAA under accelerated assessment timelines. "Given the diversity of patient populations affected by chronic hepatitis C, including the estimated 15 million
The study, approved by the Food and Drug Administration (FDA), was conducted at Northwestern Memorial Hospital. The therapeutic approach utilizing a patient’s own cells expanded in the laboratory
The formulation will be based on the Company’s proprietary ARCUS technology, and will be produced in collaboration with the Massachusetts Institute of Technology (MIT). RDS is a condition
The sNDS includes data to support: 1) High Dose Bolus administration of Aggrastat; and 2) an indication expansion for the reduction of major cardiovascular events in patients with